Orbsen Therapeutics, a spin-out from NUI Galway’s Regenerative Medicine Institute (REMEDI), will partner with the University of Birmingham in the €6 million EU FP7 funded MERLIN project to develop a cell therapy inflammatory liver disease
Orbsen Therapeutics is Irelands leading Cell Therapy biotechnology company and is a spin-out from NUI Galways’ Regenerative Medicine Institute (REMEDI). The EU FP7-funded project known by the acronym “MERLIN” (MEsynchymal stem cells to Reduce Liver INflammation) is led by Professor Phil Newsome, Clinical Director of the Birmingham University Stem Cell Centre. MERLIN will advance Orbsen’s proprietary cell therapy to a Phase 2a clinical trial in patients with inflammatory liver disease.
This MERLIN project will evaluate the Orbsen cell therapy in 4 different research laboratories across Europe and the project will culminate in a Phase 2a clinical trial of the therapy in the crippling inflammatory liver disease, Primary Sclerosing Cholangitis.
No comments:
Post a Comment